| Literature DB >> 31731809 |
Yuming Wang1, Chenghao Bi1, Wentao Pang2, Yuechen Liu1, Yu Yuan1, Huan Zhao1, Tianpu Zhang1, Yungang Zhao2, Yubo Li1.
Abstract
Gout Party is a Chinese medicine prescription composed of Aconiti Lateralis Radix Praeparaia, Aconiti Radix Cocta, Cremastrae Pseudobulbus Pleiones Pseudobulbus, Smilacis Glabrae Rhizoma, Rehmanniae Radix, and Glycyrrhizae Radix et Rhizoma, which can relieve joint pain caused by gouty arthritis (GA) and rheumatoid, and has a therapeutic effect on acute gouty arthritis (AGA). However, little information is available on the molecular biological basis and therapeutic mechanism of Gout Party for the treatment of AGA. AGA model was established by injecting sodium urate, and colchicine served as a positive control drug. We established a metabolomic method based on ultra-high-performance liquid chromatography-tandem quadrupole/time-of-flight mass spectrometry (UHPLC-Q-TOF/MS) to analyze the plasma samples of model group rats and blank group rats. Multiple statistical analyses, including principal component analysis (PCA) and partial least square discrimination analysis (PLS-DA), were used to examine metabolite profile changes in plasma samples. Finally, we identified 2-ketobutyric acid, 3-hexenedioic acid, but-2-enoic acid, and so on; 22 endogenous metabolites associated with AGA. After successful molding, we found that 2-ketobutyric acid, 3-hexenedioic acid, but-2-enoic acid, argininic acid, galactonic acid, lactic acid, equol 4'-O-glucuronide, deoxycholic acid glycine conjugate, glycocholic acid, sphinganine 1-phosphate, LPE (0:0/20:3), LPE (0:0/16:0), LPC (15:0) decreased significantly (p < 0.05 or p < 0.01), alanine, erythrulose, 3-dehydrocarnitine, m-methylhippuric acid, 3-hydroxyoctanoic acid, p-cresol sulfate, estriol 3-sulfate 16-glucuronide, 10-hydroxy-9-(phosphonooxy)octadecenoate, docosahexaenoic acid increased significantly (p < 0.05 or p < 0.01). After Gout Party treatment, 14 biomarkers had a tendency to normal conditions. These above biomarkers were mainly involved in fatty acid metabolism, bile acid metabolism, amino acid metabolism, and energy metabolism pathways. These results suggested that Gout Party exerted therapeutic effects of treating AGA by improving energy metabolism disorder and amino acid metabolism dysfunction, and attenuating fatty acid metabolism abnormal and inflammation. The results of this experiment provided a reference for revealing the metabolic mechanism produced by Gout Party in the treatment of AGA, but the subsequent studies need to be further improved and supported by relevant cell experiments and clinical experiments.Entities:
Keywords: Acute Gouty Arthritis; Biomarkers; Gout; Gout Party; Metabolomics; UHPLC–Q–TOF/MS
Mesh:
Substances:
Year: 2019 PMID: 31731809 PMCID: PMC6888674 DOI: 10.3390/ijms20225753
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Histopathological evaluation of different treated groups. (a) Blank group. (b) Model group. (c) Positive control group. (d) High dose group. (e) Low dose group. The black and yellow arrows pointed to inflammatory cells.
Figure 2The results of biochemical indicators. (a) Changes of IL–1β in plasma of different groups. (b) Changes of IL–6 in plasma of different groups. (**: Significantly increased compared with blank group (p < 0.01); #: Significantly decreased compared with model group (p < 0.05); ##: Extremely significantly decreased compared with model group (p < 0.01).
The results of the experimental methodology.
| Experiment Name | RSD (Peak Area) | RSD (Retention Time) |
|---|---|---|
| Instrument precision | <14.3% | <1.0% |
| Method repeatability | <13.7% | <1.0% |
| Sample stability | <14.8% | <1.0% |
Figure 3(a) The base peak intensity (BPI) chromatogram of plasma in the QC sample in negative mode was obtained based on the UHPLC–Q–TOF/MS platform. (b) The BPI chromatogram of chemical characterization in negative mode. (c) The BPI chromatogram of chemical characterization in positive mode.
Characterization of compounds in Gout Party
| No. | tR (min) | Fromula | Identification | Parention | MS/MS | ||
|---|---|---|---|---|---|---|---|
| 1 | 5.19 | 461.1674 | 461.1659 | C20H30O12 | Decaffeoyl-verbascoside | [M–H]− | 161.04;135.04 |
| 2 | 5.86 | 486.2701 | 486.2703 | C24H39NO9 | Mesaconine | [M+H]+ | 468.25;454.24 |
| 3 | 6.17 | 387.1321 | 387.1291 | C17H24O10 | Genipin | [M–H]− | 225.07 |
| 4 | 6.64 | 454.2778 | 454.2805 | C24H39NO7 | Fuziline | [M+H]+ | 436.28;404.28 |
| 5 | 6.86 | 358.2365 | 358.2382 | C22H31NO3 | Songorine | [M+H]+ | 340.23 |
| 6 | 7.33 | 500.2831 | 500.286 | C25H41NO9 | Aconine | [M+H]+ | 482.27;468.25 |
| 7 | 8.03 | 523.1666 | 523.1663 | C21H32O15 | Miltide | [M–H]− | 463.14;343.10 |
| 8 | 8.58 | 470.2725 | 470.2754 | C24H39NO8 | Hypaconine | [M+H]+ | 438.24;406.22 |
| 9 | 8.76 | 454.2769 | 454.2805 | C24H39NO7 | Delectinine | [M+H]+ | 436.26;404.24 |
| 10 | 9.26 | 438.2823 | 438.2856 | C24H39NO6 | Neoline | [M+H]+ | 420.27;388.24 |
| 11 | 9.64 | 468.2935 | 468.2961 | C25H41NO7 | Browniine | [M+H]+ | 450.28;436.26 |
| 12 | 9.94 | 468.2935 | 468.2961 | C25H41NO7 | Lycoctonine | [M+H]+ | 362.29; 393.30 |
| 13 | 10.59 | 422.2890 | 422.2906 | C24H39NO5 | Talatizamine | [M+H]+ | 390.26;372.25 |
| 14 | 12.07 | 452.3019 | 452.3012 | C25H41NO6 | Chasmanine | [M+H]+ | 420.27;388.24 |
| 15 | 14.26 | 606.2914 | 606.2914 | C31H43NO11 | 10-OH-Benzoylmesaco-nine | [M+H]+ | 588.27;574.26;556.25 |
| 16 | 15.99 | 623.1956 | 623.1976 | C29H36O15 | Acteoside | [M–H]− | 461.16 161.02 |
| 17 | 17.44 | 576.2809 | 576.2809 | C30H41NO10 | Unknown | [M+H]+ | 558.27;544.25;526.24 |
| 18 | 19.01 | 544.2915 | 544.2910 | C30H41NO8 | Gadenine | [M+H]+ | 512.26;494.25;484.23 |
| 19 | 21.12 | 604.3154 | 604.3122 | C32H45NO10 | Benzoylaconitine | [M+H]+ | 588.31 |
| 20 | 22.26 | 572.2848 | 572.2860 | C31H41NO9 | Pyromesaconitine | [M+H]+ | 554.27;540.25;522.24 |
| 21 | 22.35 | 574.3044 | 574.3016 | C31H43NO9 | BenzoylhypaconineS | [M+H]+ | 542.27;510.24 |
| 22 | 22.59 | 516.2947 | 516.2961 | C29H41NO7 | Unknown | [M+H]+ | 442.25;414.26 |
| 23 | 23.31 | 616.3135 | 616.3122 | C33H45NO10 | Pyrojesaconitine | [M+H]+ | 598.30;584.28;566.27 |
| 24 | 23.78 | 558.3096 | 558.3067 | C31H43NO8 | Deoxybenzoylhypaconitine | [M+H]+ | 526.27;508.27 |
| 25 | 23.88 | 648.3031 | 648.3020 | C33H45NO12 | Beiwutine | [M+H]+ | 588.29 |
| 26 | 24.95 | 556.2905 | 556.2910 | C31H41NO8 | Pyrohypaconitine | [M+H]+ | 524.26;492.23 |
| 27 | 25.25 | 586.3019 | 586.3016 | C32H43NO9 | Pyroaconitine | [M+H]+ | 568.29;554.27;472.21 |
| 28 | 25.64 | 632.3107 | 632.3071 | C33H45NO11 | 16-O-demethylaconitine | [M+H]+ | 572.28;540.25;508.22 |
| 29 | 25.64 | 632.3107 | 632.3071 | C33H45NO11 | Mesaconitine | [M+H]+ | 572.30;540.30 |
| 30 | 27.00 | 570.3082 | 570.3067 | C32H43NO8 | Pyrodeoxyaconitine | [M+H]+ | 538.27;506.25;478.22 |
| 31 | 27.11 | 616.3145 | 616.3122 | C33H45NO10 | HypaconitineS | [M+H]+ | 584.28;556.28;524.26 |
| 32 | 27.66 | 628.3131 | 628.3122 | C34H45NO10 | Anhydroaconitine | [M+H]+ | 568.28;536.26;508.26 |
| 33 | 28.33 | 700.2738 | 700.2758 | C39H41NO11 | Trifoliolasine E | [M+H]+ | 640.25;578.23 |
| 34 | 28.55 | 630.3281 | 630.3278 | C34H47NO10 | Deoxyaconitine | [M+H]+ | 598.30;570.30;538.27 |
| 35 | 28.74 | 505.3532 | 505.3529 | C30H48O6 | 16-Oxo-alisol A | [M+H]+ | 505.33;487.34 |
| 36 | 29.32 | 529.3539 | 529.3529 | C32H48O6 | Alisol C-23-acetate | [M+H]+ | 551.33;511.34 |
| 37 | 30.92 | 455.3502 | 455.3525 | C30H46O3 | Alisol I | [M+H]+ | 477.33;543.33 |
| 38 | 31.67 | 487.3411 | 487.3423 | C30H46O5 | Alisol C | [M+H]+ | 509.33;469.32 |
| 39 | 31.71 | 489.3563 | 489.3580 | C30H48O5 | Alisol F | [M+H]+ | 511.33;471.34 |
| 40 | 32.51 | 471.3463 | 471.3474 | C30H46O4 | Alisol H | [M+H]+ | 493.32;453.33 |
| 41 | 33.98 | 515.3711 | 515.3736 | C32H50O5 | Alisol B-23-acetate | [M+H]+ | 537.35;497.35 |
Figure 4Results of multivariate statistical analysis. (a) principal component analysis (PCA) 2D scores plots of blank group, control group, and administration groups of Gout Party compared with model group. (b) partial least squares pattern recognition analysis (PLS–DA) 3D scores plots of blank group, control group, and administration groups of Gout Party compared with model group.
Figure 5The receiver operating characteristic (ROC) curve to assess the predictive ability of the biomarkers of AGA.
Figure 6(a)Heatmap metabonomic data depicting the data structure of 22 biomarkers. The depth of the color represents the size of the variable. (b) Correlation metabonomic data depicting the data structure of 22 biomarkers. Red or blue represents the positive or negative correlation coefficients between metabolites, respectively.
The information of the AGA biomarkers.
| No. | tR(min) | MS/MS | PPM | Metabolites | Formula | Content Variance | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Model | High | Low | Control | ||||||||
| 1 | 0.79 | 101.0234 | 101.0239 | 53.00, | −4.95 | 2–Ketobutyric acid | C4H6O3 | ↓** | ↑ | ↑ | ↑ |
| 2 | 0.79 | 143.0344 | 143.0344 | 59.01 | 0.00 | 3–Hexenedioic acid | C6H8O4 | ↓** | ↑ | ↑ | ↑ |
| 3 | 0.79 | 85.0288 | 85.0290 | 67.01 | –2.35 | But–2–enoic acid | C4H6O2 | ↓** | ↓ | ↑ | ↑ |
| 4 | 0.81 | 174.0878 | 174.0879 | 100.08 | −0.57 | Argininic acid | C6H13N3O3 | ↓** | ↑ | ↓ | ↑ |
| 5 | 0.81 | 195.0487 | 195.0505 | 89.02 | −9.23 | Galactonic acid | C6H12O7 | ↓** | ↑ | ↑ | ↑ |
| 6 | 0.84 | 88.0394 | 88.0399 | 88.04 | −5.68 | Alanine | C3H7NO2 | ↑** | ↑ | ↓ | ↑ |
| 7 | 0.91 | 119.0342 | 119.0344 | 87.01 | −1.68 | Erythrulose | C4H8O4 | ↑* | ↓ | ↓ | ↓ |
| 8 | 0.92 | 89.0235 | 89.0239 | 71.01 | −4.49 | Lactic acid | C3H6O3 | ↓** | ↑ | ↓ | ↑ |
| 9 | 2.36 | 158.0814 | 158.0817 | 59.01 | –1.90 | 3–Dehydrocarnitine | C7H13NO3 | ↑** | ↓ | ↑ | ↓ |
| 10 | 2.41 | 192.0658 | 192.0661 | 65.04 | −1.56 | m–Methylhippuric acid | C10H11NO3 | ↑* | ↑ | ↑# | ↑ |
| 11 | 2.52 | 417.1171 | 417.1186 | 103.04 | −3.60 | Equol 4’–O–glucuronide | C21H22O9 | ↓** | ↓ | ↑## | ↓ |
| 12 | 2.88 | 159.1016 | 159.1021 | 59.01 | −3.14 | 3–Hydroxyoctanoic acid | C8H16O3 | ↑* | ↑ | ↑ | ↑ |
| 13 | 2.95 | 187.0059 | 187.0065 | 51.02 | −3.21 | p–Cresol sulfate | C7H8O4S | ↑* | ↓ | ↑# | ↑ |
| 14 | 3.08 | 448.3050 | 448.3063 | 74.02 | −2.90 | Deoxycholic acid glycine conjugate | C26H43NO5 | ↓* | ↓ | ↓## | ↓## |
| 15 | 3.09 | 465.3028 | 465.3039 | 116.04 | −2.36 | Glycocholic acid | C27H46O4S | ↓** | ↓ | ↑# | ↑# |
| 16 | 4.78 | 380.2552 | 380.2566 | 78.96 | −3.68 | Sphinganine 1–phosphate | C18H40NO5P | ↓** | ↓ | ↓ | ↓## |
| 17 | 5.69 | 502.2945 | 502.2934 | 78.96 | 2.19 | LPE (0:0/20:3) | C25H46NO7P | ↓** | ↑ | ↑ | ↑ |
| 18 | 5.76 | 452.2775 | 452.2777 | 98.99 | –0.44 | LPE (0:0/16:0) | C21H44NO7P | ↓* | ↑ | ↓ | ↑ |
| 19 | 7.04 | 480.3089 | 480.3090 | 78.96 | −0.21 | LPC (15:0) | C23H48NO7P | ↓** | ↑ | ↓# | ↑## |
| 20 | 7.75 | 543.1513 | 543.1536 | 59.01 | −4.24 | Estriol 3–sulfate 16–glucuronide | C24H32O12S | ↑* | ↓ | ↑ | ↑ |
| 21 | 7.76 | 395.2190 | 395.2199 | 62.96 | −2.28 | 10–Hydroxy–9–(phosphonooxy)octadecanoate | C18H37O7P | ↑** | ↓ | ↑ | ↑ |
| 22 | 7.76 | 327.2320 | 327.2324 | 127.08 | –1.22 | Docosahexaenoic acid | C22H32O2 | ↑** | ↓ | ↓ | ↑ |
↑**: Extremely significantly increased compared with blank group (p < 0.01); ↓**:Extremely significantly decreased compared with blank group (p < 0.01); ↑*: Significantly increased compared with blank group (p < 0.05); ↓*: Significantly decreased compared with blank group (p < 0.05); ↑##:Extremely significantly increased compared with model group (p < 0.01); ↓#: Significantly decreased compared with model group (p < 0.05); ↑#: Significantly increased compared with model group (p < 0.05); ↓##: Extremely significantly decreased compared with model group.
Figure 7Biomarker pathway map of 22 biomarkers related to AGA.
Experimental groups and dosage of each group.
| Groups | Administration | Dosage | Mode of Administration | Time |
|
|---|---|---|---|---|---|
| Blank | Saline | 15 mL/kg | Gavage | 7 days | 6 |
| Model | Saline | 15 mL/kg | Gavage | 7 days | 6 |
| Control | Colchicine | 0.8 mg/kg | Gavage | 7 days | 6 |
| GPH | Gout Party | 20 g/kg | Gavage | 7 days | 6 |
| GPL | Gout Party | 1 0g/kg | Gavage | 7 days | 6 |
UHPLC–Q–TOF/MS gradient elution method.
| T (min) | Phase A (0.1% Formic Acid in Water) | Phase B (0.1% Formic Acid Inacetonitrile) |
|---|---|---|
| 0 | 99.0 | 1.0 |
| 0.5 | 99.0 | 1.0 |
| 2 | 50.0 | 50.0 |
| 9 | 1.0 | 99.0 |
| 10 | 1.0 | 99.0 |
| 11 | 99.0 | 1.0 |
| 13 | 99.0 | 1.0 |